Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 8Lymphoma, Mantle-Cell 6Lymphoma, Large B-Cell, Diffuse 6Lymphoma 6Burkitt Lymphoma 6Small Cell Lung Carcinoma 5Lymphoma, T-Cell 4Lymphoma, Follicular 4Waldenstrom Macroglobulinemia 3Prostatic Neoplasms 3Ovarian Neoplasms 3Neuroblastoma 3Lymphoma, Large-Cell, Anaplastic 3Lymphoma, B-Cell, Marginal Zone 3Lymphoma, B-Cell 3Leukemia, Myeloid, Acute 3Immunoblastic Lymphadenopathy 3Head and Neck Neoplasms 3Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Lung Neoplasms 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hodgkin Disease 2Gastrointestinal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2

Interventions

tremelimumab 1regramostim 1osimertinib 1evolocumab 1durvalumab 1Surgical Instruments 1Radiotherapy 1Radiation 1Nivolumab 1Needles 1MLN 8237 1Ipilimumab 1Granulocyte-Macrophage Colony-Stimulating Factor 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Cancer Metastatic × MLN 8237 × Clear all
NCT04085315 2024-06-10

Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer

University of California, San Francisco

Phase 1 Recruiting
38 enrolled
Thoracic

Lung Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡